REGISTER FOR THE 2024 CONFERENCE
Shopping Cart

No products in the cart.

Cachexia

From Molecular Insights to Clinical Strategies: Delve into the complexities of cachexia, encompassing cancer cachexia, molecular mechanisms, and evolving therapeutic approaches. Discover the forefront of research aimed at understanding and combating this debilitating condition.

AllAgeingCachexiaCancer CachexiaClinical TrialsExerciseFrailtyFrom the literatureGuidelinesMuscleNutritionOther SCWD EventsSarcopenia

KLF10: a point of convergence in cancer cachexia.

Cancer-associated cachexia is a wasting syndrome entailing loss in body mass and a shortened life expectancy. There is currently no effective treatment to abrogate this syndrome, which leads to 20-30% of deaths in patients with cancer. While there have been...

๐Ÿ—“๏ธ 2024-07-15
๐Ÿ“ฐ Publication: Current Opinion In Supportive And Palliative Care
Read MoreKLF10: a point of convergence in cancer cachexia.

Preventing loss of sirt1 lowers mitochondrial oxidative stress and preserves C2C12 myotube diameter in an inย vitro model of cancer cachexia.

Cancer cachexia is a multifactorial syndrome associated with advanced cancer that contributes to mortality. Cachexia is characterized by loss of body weight and muscle atrophy. Increased skeletal muscle mitochondrial reactive oxygen species (ROS) is a contributing factor to loss of...

๐Ÿ—“๏ธ 2024-07-01
Read MorePreventing loss of sirt1 lowers mitochondrial oxidative stress and preserves C2C12 myotube diameter in an inย vitro model of cancer cachexia.

The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia.

With limited treatment options, cachexia remains a major challenge for patients with cancer. Characterizing the interplay between tumor cells and the immune microenvironment may help identify potential therapeutic targets for cancer cachexia. Herein, we investigate the critical role of macrophages...

๐Ÿ—“๏ธ 2024-03-29
๐Ÿ“ฐ Publication: Cancer Cell
Read MoreThe crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia.

Polymorphism (rs1143634) and IL-1ฮฒ Plasma Concentration as Predictors of Nutritional Disorders and Prognostic Factors in Multiple Myeloma Patients.

Multiple myeloma (MM) is a hematological neoplasm of the early precursor of B-cells. The most characteristic symptoms observed during MM include hypocalcemia, anemia, bacterial infections, and renal damage. Nutritional disorders, especially malnutrition, are noted in about 35-71% of MM patients....

๐Ÿ—“๏ธ 2024-03-24
Read MorePolymorphism (rs1143634) and IL-1ฮฒ Plasma Concentration as Predictors of Nutritional Disorders and Prognostic Factors in Multiple Myeloma Patients.

Effect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy.

Finding sensitive clinical outcome measures has become crucial in natural history studies and therapeutic trials of neuromuscular disorders. Here, we focus on 1-year longitudinal data from quantitative magnetic resonance imaging (MRI) and phosphorus magnetic resonance spectroscopy (P MRS) in a...

๐Ÿ—“๏ธ 2024-04-13
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEffect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy.

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.

Frailty is a severe, common co-morbidity associated with heart failure (HF) with preserved ejection fraction (HFpEF). The impact of frailty on HFpEF outcomes may affect treatment choices in HFpEF. The impact of frailty on HFpEF patients and any impact on...

๐Ÿ—“๏ธ 2023-12-29
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEfficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.

Longitudinal association between muscle and bone loss: Results of US and Japanese cohort studies.

Muscle and bone are physiologically interconnected, but joint changes of muscle and bone with aging, and whether the muscle-bone changes are different by sex and by country has been little studied. We examined longitudinal associations of bone mineral density (BMD)...

๐Ÿ—“๏ธ 2024-02-08
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLongitudinal association between muscle and bone loss: Results of US and Japanese cohort studies.

Streptococcal quorum sensing peptide CSP-7 contributes to muscle inflammation and wasting.

Muscle wasting diseases, such as cancer cachexia and age-associated sarcopenia, have a profound and detrimental impact on functional independence, quality of life, and survival. Our understanding of the underlying mechanisms is currently limited, which has significantly hindered the development of...

๐Ÿ—“๏ธ 2024-02-29
๐Ÿ“ฐ Publication: Biochimica Et Biophysica Acta-Molecular Basis Of Disease
Read MoreStreptococcal quorum sensing peptide CSP-7 contributes to muscle inflammation and wasting.

Cancer cachexia: biomarkers and the influence of age.

Cancer cachexia (Ccx) is a complex metabolic condition characterized by pronounced muscle and fat wasting, systemic inflammation, weakness and fatigue. Up to 30% of cancer patients succumb directly to Ccx, yet therapies that effectively address this perturbed metabolic state are...

๐Ÿ—“๏ธ 2024-02-27
๐Ÿ“ฐ Publication: Molecular Oncology
Read MoreCancer cachexia: biomarkers and the influence of age.

Chronic aryl hydrocarbon receptor activity impairs muscle mitochondrial function with tobacco smoking.

Accumulating evidence has demonstrated that chronic tobacco smoking directly contributes to skeletal muscle dysfunction independent of its pathological impact to the cardiorespiratory systems. The mechanisms underlying tobacco smoke toxicity in skeletal muscle are not fully resolved. In this study, the...

๐Ÿ—“๏ธ 2024-02-09
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreChronic aryl hydrocarbon receptor activity impairs muscle mitochondrial function with tobacco smoking.

The burden of frailty in heart failure: Prevalence, impacts on clinical outcomes and the role of heart failure medications

Frailty often coexists with heart failure (HF), which significantly aggravates the clinical outcomes of older adults. However, studies investigating the interplay between frailty and HF in older adults are scarce. We aimed to assess the prevalence of frailty using the...

๐Ÿ—“๏ธ 2024-01-30
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreThe burden of frailty in heart failure: Prevalence, impacts on clinical outcomes and the role of heart failure medications

Metabolic syndrome and cardiovascular disease in cancer survivors.

The risk of subsequent cardiovascular disease (CVD) is high in cancer survivors. Although metabolic syndrome is an established risk factor for CVD, its association with cancer survivors has not yet been established. This study aimed to clarify whether metabolic syndrome...

๐Ÿ—“๏ธ 2024-03-22
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMetabolic syndrome and cardiovascular disease in cancer survivors.

Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series.

There is no consensus on the optimal endpoint(s) in cancer cachexia trials. Endpoint variation is an obstacle when comparing interventions and their clinical value. The aim of this systematic review was to summarize and evaluate endpoints used to assess appetite...

๐Ÿ—“๏ธ 2024-02-11
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAppetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series.

Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series.

The use of patient-reported outcomes (PROMs) of quality of life (QOL) is common in cachexia trials. Patients' self-report on health, functioning, wellbeing, and perceptions of care, represent important measures of efficacy. This review describes the frequency, variety, and reporting of...

๐Ÿ—“๏ธ 2024-03-29
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreQuality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series.

Addressing cancer anorexia-cachexia in older patients: Potential therapeutic strategies and molecular pathways.

Cancer cachexia (CC) syndrome, a feature of cancer-associated muscle wasting, is particularly pronounced in older patients, and is characterised by decreased energy intake and upregulated skeletal muscle catabolic pathways. To address CC, appetite stimulants, anabolic drugs, cytokine mediators, essential amino...

๐Ÿ—“๏ธ 2024-01-12
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MoreAddressing cancer anorexia-cachexia in older patients: Potential therapeutic strategies and molecular pathways.

CACHEXIA DEFINITION

Cachexia has been defined as a loss of lean tissue mass, involving a weight loss greater than 5% of body weight in 12โ€‰months or less in the presence of chronic illness or as a body mass index (BMI) lower than 20โ€‰kg/m2. In addition, usually three of the following five criteria are required: decreased muscle strength, fatigue, anorexia, low fat-free mass index, increase of inflammation markers such as C-reactive protein or interleukin (IL)-6 as well as anaemia or low serum albumin.

Cachexia can occur in most major diseases including infections, cancer, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, and stroke.

REFERENCES
Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008;27:793โ€“799

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489โ€“495.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!